Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Time to Buy?

Key Points

• Capricor shares jumped 13.6%, opening at $9.65 versus the prior close of $8.87 and later trading near $9.80.
• Deramiocel’s Phase 3 cardiac results received the American Heart Association’s Outstanding Research Award as an FDA decision approaches; however, manufacturing validation work is outlined through 2027.
• Capricor reported a quarterly loss of $0.73 per share, wider than the $0.44 loss analysts expected, and announced a 10% workforce reduction. Analyst sentiment is mixed, with a consensus “Hold” rating.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $8.87, but opened at $9.65. Capricor Therapeutics shares last traded at $9.8020, with a volume of 832,911 shares trading hands.

Trending Headlines about Capricor Therapeutics

These are some of the CAPR headlines that stood out recently:

• Positive Sentiment: Deramiocel’s Phase 3 cardiac results received the American Heart Association’s Outstanding Research Award in Pediatric Cardiology, adding recognition to the program as the FDA decision nears. Capricor’s HOPE-3 Phase 3 Cardiac Results Win AHA Award
• Neutral Sentiment: Capricor outlined manufacturing validation work extending into 2027. That provides a view of the company’s manufacturing plans, but the timeline may also leave questions about readiness to scale if Deramiocel is approved. Capricor Outlines 2027 Manufacturing Validation
• Negative Sentiment: Third-quarter results showed a loss of $0.73 per share, wider than analysts’ $0.44 loss estimate. The company also announced a 10% workforce reduction, underscoring efforts to manage costs amid ongoing development spending. Capricor Reports Third Quarter 2026 Results

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. LADENBURG THALM/SH SH lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, July 30th. Cantor Fitzgerald upgraded Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a report on Friday, August 14th. Oppenheimer reissued an "outperform" rating on shares of Capricor Therapeutics in a research report on Thursday, October 8th. HC Wainwright lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, July 27th. Finally, Alliance Global Partners lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price target for the company. in a research note on Tuesday, July 28th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $30.25.

Capricor Therapeutics Trading Up 13.6%

The stock has a market cap of $585.63 million, a price-to-earnings ratio of -4.01 and a beta of 0.80. The company has a fifty day simple moving average of $8.06 and a 200-day simple moving average of $20.05.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.29). As a group, analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Russell Investments Group Ltd. raised its position in Capricor Therapeutics by 21.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company's stock valued at $164,000 after purchasing an additional 3,036 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Capricor Therapeutics by 151.7% in the third quarter. Commonwealth Equity Services LLC now owns 67,402 shares of the biotechnology company's stock valued at $638,000 after buying an additional 40,627 shares during the period. VestGen Advisors LLC bought a new position in shares of Capricor Therapeutics during the third quarter worth $191,000. Oppenheimer & Co. Inc. lifted its holdings in shares of Capricor Therapeutics by 169.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company's stock valued at $1,930,000 after purchasing an additional 128,067 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its position in Capricor Therapeutics by 834.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company's stock valued at $249,000 after acquiring an additional 23,495 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.